392 related articles for article (PubMed ID: 10444025)
1. Growth factors VEGF and TGF-beta1 in peritoneal dialysis.
Zweers MM; de Waart DR; Smit W; Struijk DG; Krediet RT
J Lab Clin Med; 1999 Aug; 134(2):124-32. PubMed ID: 10444025
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up.
Zweers MM; Struijk DG; Smit W; Krediet RT
J Lab Clin Med; 2001 Feb; 137(2):125-32. PubMed ID: 11174469
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis effluent.
Selgas R; del Peso G; Bajo MA; Molina S; Cirugeda A; Sánchez-Tomero JA; Castro MJ; Castro MA; Vara F
J Nephrol; 2001; 14(4):270-4. PubMed ID: 11506249
[TBL] [Abstract][Full Text] [Related]
4. Growth factors in continuous ambulatory peritoneal dialysis effluent. Their relation with peritoneal transport of small solutes.
Lai KN; Lai KB; Szeto CC; Lam CW; Leung JC
Am J Nephrol; 1999; 19(3):416-22. PubMed ID: 10393381
[TBL] [Abstract][Full Text] [Related]
5. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport.
Stompór T; Zdzienicka A; Motyka M; Dembińska-Kieć A; Davies SJ; Sulowicz W
Perit Dial Int; 2002; 22(6):670-6. PubMed ID: 12556068
[TBL] [Abstract][Full Text] [Related]
6. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
7. TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.
Kariya T; Nishimura H; Mizuno M; Suzuki Y; Matsukawa Y; Sakata F; Maruyama S; Takei Y; Ito Y
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F167-F180. PubMed ID: 28978530
[TBL] [Abstract][Full Text] [Related]
8. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.
van Esch S; Zweers MM; Jansen MA; de Waart DR; van Manen JG; Krediet RT
Perit Dial Int; 2004; 24(6):554-61. PubMed ID: 15559485
[TBL] [Abstract][Full Text] [Related]
9. Serum level of vascular endothelial growth factor is influenced by erythropoietin treatment in peritoneal dialysis patients. (Grupo de Estudios Peritoneales de Madrid).
del Peso G; Selgas R; Bajo MA; Fernández de Castro M; Aguilera A; Cirugeda A; Jiménez C
Adv Perit Dial; 2000; 16():85-9. PubMed ID: 11045267
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal transport characteristics with glucose polymer based dialysate.
Ho-dac-Pannekeet MM; Schouten N; Langendijk MJ; Hiralall JK; de Waart DR; Struijk DG; Krediet RT
Kidney Int; 1996 Sep; 50(3):979-86. PubMed ID: 8872974
[TBL] [Abstract][Full Text] [Related]
11. Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence.
Lin CY; Chen WP; Yang LY; Chen A; Huang TP
Am J Nephrol; 1998; 18(6):513-9. PubMed ID: 9845827
[TBL] [Abstract][Full Text] [Related]
12. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells.
Ha H; Cha MK; Choi HN; Lee HB
Perit Dial Int; 2002; 22(2):171-7. PubMed ID: 11990400
[TBL] [Abstract][Full Text] [Related]
13. Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential role for nitric oxide?
Douma CE; de Waart DR; Struijk DG; Krediet RT
Clin Nephrol; 1996 May; 45(5):295-302. PubMed ID: 8738660
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis.
Smit W; de Waart DR; Struijk DG; Krediet RT
Perit Dial Int; 2000; 20(5):557-65. PubMed ID: 11117247
[TBL] [Abstract][Full Text] [Related]
15. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Ustundag B; Akpolat N; Dogukan A; Akcicek F
J Nephrol; 2003; 16(2):225-30. PubMed ID: 12768069
[TBL] [Abstract][Full Text] [Related]
16. The nitric oxide donor nitroprusside intraperitoneally affects peritoneal permeability in CAPD.
Douma CE; de Waart DR; Struijk DG; Krediet RT
Kidney Int; 1997 Jun; 51(6):1885-92. PubMed ID: 9186879
[TBL] [Abstract][Full Text] [Related]
17. A chronic inflammatory infusion model of peritoneal dialysis in rats.
Margetts PJ; Kolb M; Yu L; Hoff CM; Gauldie J
Perit Dial Int; 2001; 21 Suppl 3():S368-72. PubMed ID: 11887858
[TBL] [Abstract][Full Text] [Related]
18. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
19. A comparison between 1.36% and 3.86% glucose dialysis solution for the assessment of peritoneal membrane function.
Smit W; Langedijk MJ; Schouten N; van den Berg N; Struijk DG; Krediet RT
Perit Dial Int; 2000; 20(6):734-41. PubMed ID: 11216568
[TBL] [Abstract][Full Text] [Related]
20. By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Akpolat N; Ustündag B; Duman S; Akcicek F
Perit Dial Int; 2002; 22(3):301-6. PubMed ID: 12227386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
